Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents

Definitions

• the present invention relates to a defined crystal modification of 8-cyano-1-cyclopropyl-7- (IS, 6S-2,8-diazabicyclo [4.3.0] nonan-8-yl) -6-fluoro-1,4-dihydro- 4-oxo-3-quinoline carboxylic acid, process for its preparation and its use in pharmaceutical preparations.
• CCDC is known from DE-A 19 633 805 or PCT application no. 97 903 260.4. It is then prepared by reacting 7-chloro-8-cyano-l-cyclopropyl-6-fluoro-l, 4-dihydro-4-oxo-3-quinolinecarboxylic acid with (lS, 6S) -2,8-diazabicyclo [4.3 .0] nonane in a mixture of dimethylformamide and acetonitrile in the presence of an auxiliary base. After adding water, CCDC is extracted from water with dichloromethane and isolated by removing the extractant. You get one
• the partly Amorphous powder obtained by the manufacturing process outlined above is also hygroscopic. Amorphous solids, and even more hygroscopic
• Solids are difficult to handle in galenical processing because they have low bulk densities and poor flow properties, for example.
• special working techniques and facilities are required to handle hygroscopic solids in order to achieve reproducible results, e.g. with regard to the active substance content or stability in the solid formulations produced.
• the invention is therefore based on the object of producing a crystalline form of defined modification of CCDC which, owing to its physical properties, in particular its crystal properties, is easy to handle in pharmaceutical formulations.
• the invention therefore relates to the crystalline modification D of CCDC, which is characterized in that it has an X-ray powder diffractogram with the reflex positions (2 theta) of high and medium intensity (> 30% relative intensity) given in Table 1 below.
• Table 1 :
• Modification D according to the invention of CCDC also differs from other forms of CCDC in a number of other properties. This too
• CCDC of modification D is characterized in that it has a melting point of 261 ° C. to 265 ° C., determined with the aid of differential thermal analysis (DTA) Has.
• DTA differential thermal analysis
• CCDC of modification D is characterized in that it has an infrared spectrum measured in KBr as shown in Figure 3.
• the crystal modification D of CCDC is obtained by dissolving CCDC of unknown modification or amorphous CCDC in a concentration between 1 and 3 percent by weight in water, allowing this solution to stand until a solid precipitates, filtering off this solid, drying the water-containing product thus obtained and then heated to a temperature above the transition temperature.
• the water-containing product can be dried using standard methods.
• the water-containing product can be dried in a vacuum at an elevated temperature. It is also possible to carry out the drying in the presence of a customary drying agent such as, for example, phosphorus pentoxide.
• the temperature required to convert the dried sample into modification D can be determined by means of a DTA of the dried substance. As a rule, it is between 130 ° C and 160 ° C.
• CCDC of crystal modification D is surprisingly stable and does not convert into another crystal modification or the amorphous form even after prolonged storage. For these reasons, it is ideally suited for the production of tablets or other solid formulations. Its stability gives these formulations the desired long-term storage stability. With the crystal modification D, stable and solid preparations of CCDC can be produced in a targeted manner. CCDC of crystal modification D is extremely effective against pathogenic bacteria in the field of human or veterinary medicine. Its broad area of application corresponds to that of CCDC.
• D from CCDC was obtained with a transmission diffractometer STADI-P with location-sensitive detector (PSD2) from Stoe.
• the melting point of the differential thermal analysis was obtained with the device DSC 820 from Mettler-Toledo.
• the sample of CCDC of crystal modification D was heated in air in an aluminum crucible at 5 K / min.
• the IR spectrum was obtained in KBr using the 881 device from Perkin-Elmer.
• Aetonitrile is stirred for 16 hours at room temperature.
• the reaction mixture is concentrated on a rotary evaporator at a bath temperature of 60 ° C. and the residue is taken up in 10 ml of water.
• the resulting solution is adjusted to pH 7 with dilute hydrochloric acid and the solid is filtered off.
• the filtrate is extracted three times with 20 ml dichloromethane.
• the organic phase is dried over
• 1,012 g of 7-chloro-8-cyan-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarbonic acid are mixed in a mixture of 3,300 ml of ethanol and 1,980 ml of N-methyl -pyrroli- don and 534 g of Hünig base. The mixture is heated under reflux and then dripped
• the solid obtained is in a mixture of 4,650 ml of ethanol and 41 g

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Communicable Diseases (AREA)
• Pharmacology & Pharmacy (AREA)
• Oncology (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=7899026

Family Applications (1)

Country Status (22)

Families Citing this family (5)

Family Cites Families (7)

• 1999
  • 1999-02-26 DE DE19908448A patent/DE19908448A1/de not_active Withdrawn
• 2000
  • 2000-02-14 PL PL00349394A patent/PL349394A1/xx not_active Application Discontinuation
  • 2000-02-14 EP EP00909167A patent/EP1159277A1/de not_active Withdrawn
  • 2000-02-14 UA UA2001096577A patent/UA71606C2/uk unknown
  • 2000-02-14 KR KR1020017009632A patent/KR100756474B1/ko not_active IP Right Cessation
  • 2000-02-14 SK SK1194-2001A patent/SK11942001A3/sk not_active Application Discontinuation
  • 2000-02-14 CZ CZ20013065A patent/CZ20013065A3/cs unknown
  • 2000-02-14 JP JP2000602236A patent/JP2002538159A/ja not_active Withdrawn
  • 2000-02-14 CA CA002362804A patent/CA2362804A1/en not_active Abandoned
  • 2000-02-14 AU AU31544/00A patent/AU760710B2/en not_active Ceased
  • 2000-02-14 CN CN00804306XA patent/CN1217944C/zh not_active Expired - Fee Related
  • 2000-02-14 BR BR0008520-0A patent/BR0008520A/pt not_active IP Right Cessation
  • 2000-02-14 IL IL14452800A patent/IL144528A0/xx not_active IP Right Cessation
  • 2000-02-14 HU HU0200053A patent/HUP0200053A3/hu unknown
  • 2000-02-14 US US09/914,031 patent/US6492391B1/en not_active Expired - Fee Related
  • 2000-02-14 WO PCT/EP2000/001203 patent/WO2000052010A1/de not_active Application Discontinuation
  • 2000-02-14 RU RU2001126301/04A patent/RU2248357C2/ru not_active IP Right Cessation
  • 2000-02-14 TR TR2001/02435T patent/TR200102435T2/xx unknown
  • 2000-02-14 NZ NZ513749A patent/NZ513749A/en unknown
• 2001
  • 2001-07-24 ZA ZA200106050A patent/ZA200106050B/en unknown
  • 2001-08-21 NO NO20014059A patent/NO320314B1/no unknown
• 2002
  • 2002-09-12 HK HK02106690.8A patent/HK1045158B/zh not_active IP Right Cessation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events